Cumulative incidences of MMR, MR4.0, and MR4.5, performed with competing risk regression. Competing risks events are defined as any event that would result in permanent asciminib discontinuation on study. The cumulative incidence of MMR was 77.2% (95% CI, 67.6-84.3) and 87.1% (95% CI, 76.4-93.1) by 12 and 24 months, respectively. The cumulative incidence of MR4 was 48.5% (95% CI, 38.4-57.9) and 64.9% (95% CI, 51.6-75.4) by 12 and 24 months, respectively. The cumulative incidence of MR4.5 was 30.0% (95% CI, 21.3-39.2) and 52.9% (95% CI, 39.7-64.5) by 12 and 24 months, respectively.